New research published online in the FASEB Journal suggests that a specific enzyme, called 5-lipoxygenase, plays a key role in cell death induced by microgravity environments, and that inhibiting this enzyme will likely help prevent or lessen the severity of immune problems in astronauts caused by spaceflight. Additionally, since space conditions initiate health problems that mimic the aging process on Earth, this discovery may also lead to therapeutics that extend lives by bolstering the immune systems of the elderly.
"The outcomes of this space research might be helpful to improve health in the elderly on Earth," said Mauro Maccarrone, Ph.D., a researcher involved in the work from the Department of Biomedical Sciences at the University of Teramo in Teramo, Italy. "In fact, space conditions [cause problems that] resemble the physiological process of aging and drugs able to reduce microgravity-induced immunodepression might be effective therapeutics against loss of immune performance in aging people. 5-lipoxygenase inhibitors, already used to curb human inflammatory diseases, may be such a group of compounds."
Maccarone and colleagues made this discovery by conducting experiments involving two groups of human lymphocytes that were isolated from the blood of two healthy donors. The first group of lymphocytes was exposed to microgravity onboard the International Space Station (ISS). The second group was put in a centrifuge onboard the ISS, to have the same "Space environment" as the other group, but a normal Earth-like force of gravity. When programmed cell death (apoptosis) was measured in both groups, the lymphocytes exposed to microgravity showed an increase above what is considered "normal." The group exposed to the simulated Earth gravity showed no unusual differences. Specifically, the researchers believe that this difference is caused by different levels of the 5-lipoxygenase enzyme.
"It's no surprise that bodies need Earth's gravity to function properly," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal, "because we evolved to survive on this planet. As humanity moves into space and potentially to other planets or asteroids, it's clear that we need know how not only to secure habitable conditions, but also how to secure our health. Fortunately, as we learn how to cope with low gravity environments, we also unlock secrets to longevity back home on Earth."
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB) and celebrated its 25th anniversary in 2011. Over the past quarter century, the journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information. FASEB comprises 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve—through their research—the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to its member societies and collaborative advocacy.
Details: Natalia Battista, Maria A. Meloni, Monica Bari, Nicolina Mastrangelo, Grazia Galleri, Cinzia Rapino, Enrico Dainese, Alessandro Finazzi Agrò, Proto Pippia, and Mauro Maccarrone. 5-Lipoxygenase-dependent apoptosis of human lymphocytes in the International Space Station: data from the ROALD experiment. FASEB J May 2012 26:1791-1798; doi:10.1096/fj.11-199406 ; http://www.fasebj.org/content/26/5/1791.abstract
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.